Clinical Trial Update: Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the safety and efficacy of oral PTK787 (Vatalanib) in patients with subfoveal choroidal neovascularization secondary to wet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• PTK787 (Vatalanib)

Snippet

Sponsor: Novartis | Conditions: Wet Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED